Randomized Withdrawal Study in Patients With Schizophrenia (NCT06961968)
A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
Who can join: Review the eligibility criteria below.
Location: Vanda Investigational Site — Rogers, Arkansas
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- Vanda Investigational Site — Rogers, Arkansas
- Vanda Investigational Site — Costa Mesa, California
- Vanda Investigational Site — Lemon Grove, California
- Vanda Investigational Site — Oceanside, California
- Vanda Investigational Site — Pico Rivera, California
- Vanda Investigational Site — San Diego, California
- Vanda Investigational Site — Walnut Creek, California
- Vanda Investigational Site — North Miami, Florida
- Vanda Investigational Site — Atlanta, Georgia
- Vanda Investigational Site — Peachtree Corners, Georgia
- Vanda Investigational Site — Chicago, Illinois
- Vanda Investigational Site — Flowood, Mississippi
- Vanda Investigational Site — Saint Charles, Missouri
- Vanda Investigational Site — St Louis, Missouri
- Vanda Investigational Site — Las Vegas, Nevada
- Vanda Investigational Site — Marlton, New Jersey
- Vanda Investigational Site — Staten Island, New York
- Vanda Investigational Site — Austin, Texas
- Vanda Investigational Site — Houston, Texas
- Vanda Investigational Site — Irving, Texas
- Vanda Investigational Site — Richardson, Texas
- Vanda Investigational Site — Bellevue, Washington
📞 Contact the Study Coordinator
Phone: (202) 734-3400
Email: clinicaltrials@vandapharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Schizophrenia
- Young Adults With Violent Behavior During Early Psychosis (Aim 2) — New York, New York
- Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia — Toronto, Ontario
- Ketogenic Diet in People With Schizophrenia — Catonsville, Maryland
- Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia — Toronto, Ontario
- Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography — Toronto, Ontario
- Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia — Suwanee, Georgia
Explore by condition: All Schizophrenia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.